Arbutus Biopharma (NASDAQ:ABUS) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $(0.04) by 2275 percent. This is a 769.23 percent increase over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $179.126 million which beat the analyst consensus estimate of $750.000 thousand by 23.78K percent. This is a 10.05K percent increase over sales of $1.764 million the same period last year.